Your browser doesn't support javascript.
loading
Phenotypic screening-the fast track to novel antibody discovery.
Minter, Ralph R; Sandercock, Alan M; Rust, Steven J.
Affiliation
  • Minter RR; Department of Antibody Discovery and Protein Engineering, MedImmune, Milstein Building, Granta Park, Cambridge CB21 6GH, UK.
  • Sandercock AM; Department of Antibody Discovery and Protein Engineering, MedImmune, Milstein Building, Granta Park, Cambridge CB21 6GH, UK.
  • Rust SJ; Department of Antibody Discovery and Protein Engineering, MedImmune, Milstein Building, Granta Park, Cambridge CB21 6GH, UK. Electronic address: rusts@medimmune.com.
Drug Discov Today Technol ; 23: 83-90, 2017 Mar.
Article in En | MEDLINE | ID: mdl-28647091
The majority of antibody therapeutics have been isolated from target-led drug discovery, where many years of target research preceded drug program initiation. However, as the search for validated targets becomes more challenging and target space becomes increasingly competitive, alternative strategies, such as phenotypic drug discovery, are gaining favour. This review highlights successful examples of antibody phenotypic screens that have led to clinical drug candidates. We also review the requirements for performing an effective antibody phenotypic screen, including antibody enrichment and target identification strategies. Finally, the future impact of phenotypic drug discovery on antibody drug pipelines will be discussed.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antibodies Type of study: Diagnostic_studies / Screening_studies Limits: Humans Language: En Journal: Drug Discov Today Technol Year: 2017 Document type: Article Country of publication: Reino Unido

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antibodies Type of study: Diagnostic_studies / Screening_studies Limits: Humans Language: En Journal: Drug Discov Today Technol Year: 2017 Document type: Article Country of publication: Reino Unido